Published in Lung Cancer on October 14, 2013
Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science (2014) 4.34
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer (2015) 0.98
A Systemic Review of Resistance Mechanisms and Ongoing Clinical Trials in ALK-Rearranged Non-Small Cell Lung Cancer. Front Oncol (2014) 0.93
Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib. Onco Targets Ther (2015) 0.90
Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments. J Oncol (2015) 0.86
De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. Lung Cancer (2016) 0.84
STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer. Cell Cycle (2016) 0.83
Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features. Oncotarget (2014) 0.80
Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway. Oncotarget (2016) 0.79
Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors. Am J Cancer Res (2014) 0.79
Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group. J Clin Endocrinol Metab (2015) 0.76
AREG triggered EGFR activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by EGFR inhibitors. Cancer Sci (2016) 0.76
Anaplastic lymphoma kinase: Role in cancer and therapy perspective. Cancer Biol Ther (2015) 0.76
Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells. Neoplasia (2016) 0.76
Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol (2015) 0.76
Resistance to ALK inhibitors: Pharmacokinetics, mutations or bypass signaling? Cell Cycle (2016) 0.75
The pharmacogenomics of drug resistance to protein kinase inhibitors. Drug Resist Updat (2016) 0.75
Bilateral breast adenocarcinomas with EML4-ALK fusion in a patient with multiple metastases successfully treated with crizotinib: is lung the primary site? Onco Targets Ther (2016) 0.75
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications. Dis Markers (2016) 0.75
Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance. Protein Cell (2016) 0.75
Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib. Br J Cancer (2016) 0.75
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat Rev Clin Oncol (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med (2010) 8.59
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res (2012) 6.23
New driver mutations in non-small-cell lung cancer. Lancet Oncol (2011) 6.03
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer (2009) 3.37
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol (2011) 3.00
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol (2013) 2.90
ALK in lung cancer: past, present, and future. J Clin Oncol (2013) 2.70
Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol (2012) 1.97
Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist (2012) 1.88
Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res (2012) 1.71
Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol (2012) 1.66
Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med (2012) 1.59
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol (2013) 1.39
Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation. J Thorac Oncol (2012) 0.91
Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer (2012) 0.86